Grey Wolf

News

Immuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase tumour visibility.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.